Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3176
Marti Technologies
MRT
$161M
| $195K | ﹤0.01% |
64,500
+45,412
| +238% | +$133K |
2024 Q4
2 quarters
|
|
|
TBI
3177
Trueblue
TBI
$270M
| $194K | ﹤0.01% |
+29,900
| New | +$161K |
2025 Q2
0 quarters
|
|
|
IOBT
3178
DELISTED
IO Biotech
IOBT
| $194K | ﹤0.01% |
139,300
+12,900
| +10% | +$14.8K |
2022 Q3
11 quarters
|
|
3179
Rhinebeck Bancorp
RBKB
$201M
| $194K | ﹤0.01% |
+16,500
| New | +$183K |
2025 Q2
0 quarters
|
|
|
SGRP
3180
DELISTED
SPAR Group
SGRP
| $193K | ﹤0.01% |
201,300
-6,285
| -3% | -$6.85K |
2020 Q4
18 quarters
|
|
3181
Cabaletta Bio
CABA
$327M
| $192K | ﹤0.01% |
126,100
+115,200
| +1,057% | +$180K |
2024 Q4
2 quarters
|
|
3182
Minerva Neurosciences
NERV
$152M
| $191K | ﹤0.01% |
111,000
-3,097
| -3% | -$5.06K |
2016 Q1
37 quarters
|
|
|
APLS
3183
DELISTED
Apellis Pharmaceuticals
APLS
| $190K | ﹤0.01% |
+10,988
| New | +$203K |
2025 Q2
0 quarters
|
|
3184
Enlivex Ltd
ENLV
$5.06M
| $189K | ﹤0.01% |
11,226
-860
| -7% | -$12.8K |
2016 Q2
36 quarters
|
|
3185
Comstock
LODE
$168M
| $188K | ﹤0.01% |
49,508
-15,300
| -24% | -$42.6K |
2021 Q3
15 quarters
|
|
3186
Cocrystal Pharma
COCP
$20.6M
| $186K | ﹤0.01% |
125,028
-600
| -0.5% | -$893 |
2019 Q3
23 quarters
|
|
3187
Brilliant Earth
BRLT
$26.7M
| $185K | ﹤0.01% |
134,600
+1,800
| +1% | +$2.61K |
2022 Q2
12 quarters
|
|
|
JBS
3188
JBS N.V.
JBS
$42.7B
| $181K | ﹤0.01% |
+12,538
| New | +$176K |
2025 Q2
0 quarters
|
|
|
FGC
3189
FG Communities Holdings Inc. Common Stock
FGC
$31.6M
| $180K | ﹤0.01% |
2,246
-60
| -3% | -$5.03K |
2015 Q3
39 quarters
|
|
3190
Better Home & Finance Holding
BETR
$187M
| $179K | ﹤0.01% |
+14,452
| New | +$187K |
2025 Q2
0 quarters
|
|
3191
Sportsman's Warehouse
SPWH
$43.1M
| $179K | ﹤0.01% |
51,800
-297,700
| -85% | -$667K |
2024 Q4
2 quarters
|
|
|
NSTS
3192
DELISTED
NSTS Bancorp
NSTS
| $178K | ﹤0.01% |
14,400
| – | – |
2024 Q4
2 quarters
|
|
|
RAPP
3193
Rapport Therapeutics
RAPP
$1.47B
| $177K | ﹤0.01% |
+15,600
| New | +$166K |
2025 Q2
0 quarters
|
|
|
ZENV
3194
DELISTED
Zenvia
ZENV
| $177K | ﹤0.01% |
118,201
-15,000
| -11% | -$22.2K |
2022 Q1
13 quarters
|
|
3195
Metagenomi Therapeutics
MGX
$37.8M
| $176K | ﹤0.01% |
119,000
+19,400
| +19% | +$30.4K |
2024 Q3
3 quarters
|
|
3196
Celcuity
CELC
$3.32B
| $175K | ﹤0.01% |
+13,100
| New | +$143K |
2025 Q2
0 quarters
|
|
3197
Quantum-Si Incorporated
QSI
$335M
| $175K | ﹤0.01% |
89,200
-782,556
| -90% | -$1.16M |
2024 Q3
3 quarters
|
|
3198
Dare Bioscience
DARE
$15.2M
| $172K | ﹤0.01% |
71,795
+1,200
| +2% | +$3.5K |
2022 Q1
13 quarters
|
|
|
AHG
3199
Akso Health Group
AHG
$1.07B
| $170K | ﹤0.01% |
130,798
-14,400
| -10% | -$19.3K |
2018 Q3
27 quarters
|
|
3200
Outlook Therapeutics
OTLK
$146M
| $170K | ﹤0.01% |
+106,068
| New | +$169K |
2025 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.